Table 2.
Pyknotic index, pyramidal cell layer in the hippocampus (CA1, CA2, CA3, and CA4), and granular cell layer in the dentate gyrus after 4 weeks of vehicle, CBD, CBD lipid nanoparticles (CBD-LNP), or levodopa (L-dopa) treatments in diabetic Parkinson’s disease (DP) rats.
| Parameters | Control Group | DP Group | |||
|---|---|---|---|---|---|
| Vehicle | Vehicle | CBD | CBD-LNP | L-Dopa | |
| Pyknotic index of the CA1 (%) | 7.70 ± 3.25 | 22.59 ± 12.91 ** | 11.50 ± 4.30 † | 9.78 ± 5.01 †† | 7.86 ± 0.84 †† |
| Pyknotic index of the CA2 (%) | 6.13 ± 1.67 | 40.32 ± 14.39 *** | 8.86 ± 3.94 †† | 12.45 ± 5.61 †† | 34.39 ± 10.39 ** |
| Pyknotic index of the CA3 (%) | 6.78 ± 0.97 | 38.96 ± 10.41 ** | 14.00 ± 0.86 † | 6.12 ± 2.41 †† | 14.21 ± 4.48 † |
| Pyknotic index of the CA4 (%) | 7.84 ± 3.82 | 55.95 ± 9.98 ** | 8.22 ± 2.24 †† | 14.12 ± 7.04 †† | 21.61 ± 15.31 † |
| Pyknotic index of the DG (%) | 6.39 ± 3.76 | 25.83 ± 8.51 ** | 10.04 ± 0.84 † | 11.05 ± 4.90 † | 14.51 ± 5.73 † |
| Thickness of the pyramidal cell layer in the CA1 (µm) | 47.28 ± 1.19 | 31.99 ± 1.72 *** | 47.47 ± 1.95 ††† | 48.51 ± 1.45 ††† | 45.8 ± 1.26 ††† |
| Thickness of the pyramidal cell layer in the CA2 (µm) | 55.69 ± 1.98 | 47.67 ± 2.27 *** | 51.28 ± 1.52 † | 52.89 ± 1.83 †† | 48.48 ± 1.44 * |
| Thickness of the pyramidal cell layer in the CA3 (µm) | 57.47 ± 1.15 | 39.97 ± 1.30 *** | 51.19 ± 1.32 *††† | 54.45 ± 1.71 ††† | 51.72 ± 1.36 *††† |
| Thickness of the pyramidal cell layer in the CA4 (µm) | 93.29 ± 3.33 | 70.16 ± 2.38 *** | 82.63 ± 3.56 † | 88.23 ± 3.42 ††† | 89.10 ± 2.17 ††† |
| Thickness of the granular cell layer in the DG (µm) | 64.07 ± 1.91 | 50.14 ± 1.73 *** | 58.36 ± 1.08 †† | 61.08 ± 1.62 ††† | 62.18 ± 1.15 ††† |
Data are presented as mean ± SEM (n = 3–4 rats/group). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to vehicle-treated control group. † p < 0.05, †† p < 0.01, ††† p < 0.001 compared to vehicle treated-DP group.